Acute kidney injury (AKI) is characterized by a sudden loss in kidney function, characterized increasing serum creatinine level without loss of urine. Acute kidney injury affects other organs of the human body such as heart, lungs, and brain. Acute kidney injury is most common in patients admitted at hospital, intensive care units (ICU), and among older adults. Signs and symptoms of acute kidney failure may include decreased urine output, although occasionally urine output remains normal, fluid retention, causing swelling in legs, ankles or feet, shortness of breath, fatigue, confusion, nausea, weakness, irregular heartbeat, chest pain or pressure, and seizures or coma in severe cases.
Market Dynamics
Key players operating in the global acute kidney injury treatment market are focusing on adoption of growth strategies such as product launch, regulatory approval, and research and development for the treatment of acute kidney injury, which is expected to drive the market growth during the forecast period. For instance, in October 2019, Astellas Pharma Inc. is a Japanese multinational pharmaceutical company., announced that the U.S. Food and Drug Administration (FDA) granted fast track designation for the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury (AKI) after coronary artery bypass and/or valve (CABG/V) surgery. The fast track designation is intended to facilitate the development, and expedite the US FDA review, of drugs to treat serious and life-threatening conditions so that, if approved, the compounds can reach the market more expeditiously. Furthermore, in April 2021, Angion Biomedica Corp a late-stage biopharmaceutical company and Vifor Pharma a global pharmaceutical company announced completion of enrollment for Angion’s AKI-002-15 study, a Phase II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2020.
Key features of the study:
- This report provides in-depth analysis of the global acute kidney injury treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global acute kidney injury treatment market based on the following parameters – company highlights, product portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V, Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global acute kidney injury treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute kidney injury treatment market
Detailed Segmentation:
- Global Acute Kidney Injury Treatment Market, By Type :
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- Global Acute Kidney Injury Treatment Market, By Treatment :
- Global Acute Kidney Injury Treatment Market, By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Acute Kidney Injury Treatment Market, By Region:
- North America
- By Type
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- By Treatment
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Type
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- By Treatment
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Type
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- By Treatment
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Type
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- By Treatment
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Type
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- By Treatment
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Type
- Prerenal Acute Kidney Injury
- Intrinsic Renal Acute Kidney Injury
- Postrenal Acute Kidney Injury
- By Treatment
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Quark Pharmaceuticals, Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Baxter International, Inc.
- Novartis AG
- B. Braun Melsungen AG
- Fresenius Medical Care
- Medtronic
- Astellas Pharma Inc.
- Sentien Biotechnologies, Inc.
- Teva Pharmaceutical Industries Ltd.
- Asahi Kasei Medical Co.
- AM-Pharma B.V.
- Teleflex Incorporated
- Cure Medical, LLC
- Angion Biomedia Corp
“*” marked represents similar segmentation in other categories in the respective section.
